Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| TeraWulf Inc | Paul Prager B. | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 7,849,294 | 7,849,294 | - | - | Restricted Stock Units | |
| TeraWulf Inc | M. Khan Nazar | Director, Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 6,541,078 | 6,541,078 | - | - | Restricted Stock Units | |
| TeraWulf Inc | B. Paul Prager | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 3,924,647 | 3,924,647 | - | - | Performance-Based Restricted Stock Units | |
| TeraWulf Inc | Khan Nazar M. | Director, Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 3,270,539 | 3,270,539 | - | - | Performance-Based Restricted Stock Units | |
| Ocugen Inc | Shankar Musunuri | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 3,123,201 | 4,955,924 (9%) | 5% | 0 | Common Stock | |
| Ocugen Inc | Shankar Musunuri | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 3,123,201 | 3,123,201 | - | - | Option (Right to Buy) | |
| Warner Bros. (Class A) | David M. Zaslav | Director, Chief Executive Officer & Pres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 3,052,734 | 3,052,734 | - | - | Employee Stock Option (right to acquire) | |
| TeraWulf Inc | Fleury Patrick A. | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 2,616,431 | 2,616,431 | - | - | Restricted Stock Units | |
| TeraWulf Inc | M. Kerri Langlais | Director, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 2,616,431 | 2,616,431 | - | - | Restricted Stock Units | |
| Compass Therapeutics Inc | Thomas J. Schuetz | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 2,000,000 | 2,000,000 | - | - | Stock Option (Right to Buy) | |
| Gossamer Bio Inc | Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 1,680,000 | 1,680,000 | - | - | Stock Option (Right to Buy) | |
| TeraWulf Inc | M. Kerri Langlais | Director, Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 1,308,216 | 1,308,216 | - | - | Performance-Based Restricted Stock Units | |
| TeraWulf Inc | Patrick A. Fleury | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 1,308,216 | 1,308,216 | - | - | Performance-Based Restricted Stock Units | |
| Kura Oncology Inc | Troy E. Wilson | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 1,120,000 | 1,120,000 | - | - | Option to purchase common stock | |
| Compass Therapeutics Inc | Prasad Arjun | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 1,000,000 | 1,000,000 | - | - | STOCK OPTION (RIGHT TO BUY) | |
| The Baldwin Insurance Grp Inc (Class A) | Paul Eugene Sparks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 982,606 | 982,606 (5%) | 5% | - | Class A Common Stock | |
| ARS Pharma Inc | Richard E. Lowenthal | Director, PRESIDENT AND CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 875,000 | 875,000 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Sarina Tanimoto | CHIEF MEDICAL OFFICER, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 875,000 | 875,000 | - | - | Stock Option (right to buy) | |
| Twenty One Capital Inc | Steven Meehan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 796,951 | 796,951 | - | - | Stock Option (Right to Buy) | |
| Design Therapeutics Inc | Pratik Shah | Director, President, CEO and Chairperson | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 750,000 | 750,000 | - | - | Stock option (right to buy) | |
| Freshworks Inc (Class A) | Dennis M. Woodside | Director, CEO & President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 725,221 | 2,738,490 | - | 0 | Class A Common Stock | |
| Compass Therapeutics Inc | Jonathan Anderman | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 720,000 | 720,000 | - | - | Stock Option (Right to Buy) | |
| Gossamer Bio Inc | Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 693,750 | 693,750 | - | - | Stock Option (Right to Buy) | |
| ORIC Pharma Inc | Jacob M. Chacko | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 675,000 | 675,000 | - | - | Stock Option (right to buy) | |
| Compass Therapeutics Inc | Barry Shin | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 670,000 | 670,000 | - | - | Stock Option (Right to Buy) | |
| Innovative Eyewear Inc | Vladimir Galkin | Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 1.79 per share. | 02 Jan 2026 | 643,505 | 0 | - | 1.8 | 1,151,874 | Common Stock, par value $0.00001 |
| Evolent Health Inc (Class A) | Mario Ramos | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 587,500 | 587,500 (0%) | 0% | 0 | Class A Common Stock | |
| Gossamer Bio Inc | Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 562,500 | 562,500 | - | - | Stock Option (Right to Buy) | |
| Gossamer Bio Inc | Robert Paul Smith | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 562,500 | 562,500 | - | - | Stock Option (Right to Buy) | |
| Gossamer Bio Inc | Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 506,250 | 506,250 | - | - | Stock Option (Right to Buy) | |
| Gossamer Bio Inc | Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 506,250 | 506,250 | - | - | Stock Option (Right to Buy) | |
| SharkNinja Inc | Mark Barrocas | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 500,000 | 500,000 | - | - | Restricted Share Units | |
| Pearson PLC (ADR) | Omar P Abbosh | Executive Director,Chief Executive Officer | 02 Jan 2026 | 472,951 | 857,804 (0%) | 0% | 0 | Ords 0.25p | ||
| Atlassian Corp (Class A) | Michael Cannon-Brookes | Director, CEO, Co-Founder, Ten Percent Owner | 02 Jan 2026 | 467,565 | 47,066,808 | - | - | Class B Common Stock | ||
| Atlassian Corp (Class A) | Farquhar Scott | Director, Ten Percent Owner | 02 Jan 2026 | 467,565 | 467,565 (0%) | 0% | - | Class A Common Stock | ||
| Atlassian Corp (Class A) | Scott Farquhar | Director, Ten Percent Owner | 02 Jan 2026 | 467,565 | 47,066,808 | - | - | Class B Common Stock | ||
| Atlassian Corp (Class A) | Michael Cannon-Brookes | Director, CEO, Co-Founder, Ten Percent Owner | 02 Jan 2026 | 467,565 | 467,565 (0%) | 0% | - | Class A Common Stock | ||
| Navan Inc Ordinary Shares | Benjamin A. Horowitz | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 16.27 per share. | 02 Jan 2026 | 466,058 | 7,789,538 | - | 16.3 | 7,582,764 | Class A Common Stock |
| UDR | Thomas W. Toomey | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 453,010 | 1,183,411 | - | - | Class 2 LTIP Units | |
| Hormel Foods | Jeffrey M. Ettinger | Director, Interim CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 436,300 | 436,300 | - | - | Stock Options (Right to Buy) | |
| Sionna Therapeutics Inc | Michael Cloonan | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 436,100 | 436,100 | - | - | Non-Qualified Stock Option (right to buy) | |
| Compass Therapeutics Inc | Neil Lerner | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 435,000 | 435,000 | - | - | Stock Option (Right to Buy) | |
| Netflix | Reed Hastings | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 426,290 | 0 | - | - | Non-Qualified Stock Option (right to buy) | |
| Netflix | Reed Hastings | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.31 per share. | 02 Jan 2026 | 426,290 | 430,230 (0%) | 0% | 9.3 | 3,969,186 | Common Stock |
| Intuitive Machines Inc (Class A) | Stephen Altemus | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 416,086 | 1,442,488 | - | - | Class A Common Stock | |
| Intuitive Machines Inc (Class A) | Stephen Altemus | Director, Chief Executive Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Jan 2026 | 416,086 | 12,842,213 | - | - | Class C Common Stock | |
| Intuitive Machines Inc (Class A) | Stephen Altemus | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 18.08 per share. | 02 Jan 2026 | 416,086 | 1,026,402 | - | 18.1 | 7,524,707 | Class A Common Stock |
| Intuitive Machines Inc (Class A) | Stephen Altemus | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 416,086 | 12,842,213 | - | - | Common Units | |
| Cartesian Therapeutics Inc | Carsten Brunn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 415,700 | 415,700 | - | - | Employee Stock Option (right to buy) | |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 406,000 | 406,000 | - | - | Stock Option (Right to Buy) | |
| Design Therapeutics Inc | Sean Jeffries | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 375,000 | 375,000 | - | - | Stock option (right to buy) | |
| Silence Therapeutics PLC (ADR) | Rhonda L. Hellums | Director, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 375,000 | 375,000 | - | - | Employee Share Option (Right to Buy) | |
| LENZ Therapeutics Inc | Evert B. Schimmelpennink | Director, President, CEO and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 358,100 | 358,100 | - | - | Stock Option (right to buy) | |
| Freshworks Inc (Class A) | Mika Yamamoto | Chief Integr Cust Growth Offcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 344,827 | 1,091,421 | - | 0 | Class A Common Stock | |
| Sempra Energy | Jeffrey Walker Martin | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 343,856 | 343,856 | - | - | Employee Stock Option (right to buy) | |
| Freshworks Inc (Class A) | Tyler R. Sloat | Chief Financial & Oper Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 340,854 | 1,460,638 | - | 0 | Class A Common Stock | |
| Janux Therapeutics Inc | Campbell David | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 338,100 | 338,100 | - | - | Stock option (right to buy) | |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 331,000 | 331,000 | - | - | Stock Option (Right to Buy) | |
| Bicycle Therapeutics PLC (ADR) | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 330,000 | 330,000 | - | - | Employee Stock Option (right to buy) | |
| Ocugen Inc | Ramesh Ramachandran | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 310,950 | 310,950 | - | - | Option (Right to Buy) | |
| Navan Inc Ordinary Shares | Benjamin A. Horowitz | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 16.74 per share. | 02 Jan 2026 | 308,188 | 8,300,455 | - | 16.7 | 5,159,067 | Class A Common Stock |
| Nasdaq | Adena T. Friedman | Director, Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.22 per share. | 02 Jan 2026 | 300,000 | 2,224,903 (1%) | 0% | 22.2 | 6,666,000 | Common Stock, par value $0.01 per share |
| Nasdaq | Adena T. Friedman | Director, Chair and CEO | Sale of securities on an exchange or to another person at price $ 96.39 per share. | 02 Jan 2026 | 300,000 | 1,924,903 (1%) | 0% | 96.4 | 28,917,000 | Common Stock, par value $0.01 per share |
| Nasdaq | Adena T. Friedman | Director, Chair and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 300,000 | 506,451 | - | - | Employee Stock Option (Right to Buy) | |
| Silence Therapeutics PLC (ADR) | Steven Joseph Romano | EVP and Chief R&D Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 300,000 | 300,000 | - | - | Employee Share Option (Right to Buy) | |
| Twenty One Capital Inc | James Cong Hoan Nguyen | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 297,029 | 297,029 | - | - | Stock Option (Right to Buy) | |
| Gossamer Bio Inc | Faheem Hasnain | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 280,000 | 837,793 (1%) | 0% | 0 | Common Stock | |
| Strata Critical Medical Inc (Class A) | Melissa M. Tomkiel | Director, Co-CEO and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.18 per share. | 02 Jan 2026 | 276,960 | 1,643,362 | - | 0.2 | 49,853 | Class A common stock, $0.0001 par value per share |
| Strata Critical Medical Inc (Class A) | Melissa M. Tomkiel | Director, Co-CEO and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 276,960 | 0 | - | - | Stock Option (right to buy) | |
| Genelux Corp | Jason Litten | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 275,000 | 275,000 | - | - | Stock Option (Right to Buy) | |
| MFA Fin Inc | Craig L. Knutson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 273,938 | 1,700,452 | - | - | Phantom Shares | |
| Netflix | Reed Hastings | Director | Sale of securities on an exchange or to another person at price $ 91.18 per share. | 02 Jan 2026 | 263,768 | 166,462 (0%) | 0% | 91.2 | 24,050,656 | Common Stock |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 262,391 | 335,276 | - | - | Restricted Share Units | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 262,391 | 861,642 (0%) | 0% | - | Common Shares | |
| JBG SMITH Properties | W. Matthew Kelly | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 259,259 | 2,787,793 | - | - | AO LTIP | |
| Freshworks Inc (Class A) | Mika Yamamoto | Chief Integr Cust Growth Offcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 256,244 | 746,594 | - | 0 | Class A Common Stock | |
| Apogee Therapeutics Inc | Michael Henderson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 253,016 | 253,016 | - | - | Stock Option (Right to Buy) | |
| Phathom Pharma Inc | Basta Steven L. | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 251,034 | 364,820 (1%) | 1% | 0 | Common Stock | |
| Compass Therapeutics Inc | Thomas J. Schuetz | Director, CEO | Grant, award, or other acquisition of securities at price $ 5.17 per share. | 02 Jan 2026 | 250,000 | 6,686,800 | - | 5.2 | 1,292,500 | Common Stock |
| Design Therapeutics Inc | Chris Storgard | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 250,000 | 250,000 | - | - | Stock option (right to buy) | |
| Ocular Therapeutix Inc | Jeffrey S. Heier | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,932 | 240,932 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Donald Notman | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,932 | 240,932 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Nadia Waheed | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,932 | 240,932 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,932 | 240,932 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Namrata Saroj | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,932 | 240,932 | - | - | Stock Option (Right to Buy) | |
| ARS Pharma Inc | Alexander A. Fitzpatrick | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,000 | 240,000 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Brian T. Dorsey | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,000 | 240,000 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Richard E. Lowenthal | Director, PRESIDENT AND CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,000 | 240,000 | - | - | Stock Option (right to buy) | |
| ARS Pharma Inc | Kathleen D. Scott | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,000 | 240,000 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Sarina Tanimoto | CHIEF MEDICAL OFFICER, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,000 | 240,000 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Eric Karas | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,000 | 240,000 | - | - | Stock option (right to buy) | |
| ARS Pharma Inc | Justin Chakma | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 240,000 | 240,000 | - | - | Stock option (right to buy) | |
| Jasper Therapeutics Inc | Ronald A. Martell | Director, President, CEO and Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 234,000 | 234,000 | - | - | Stock Option (right to buy) | |
| Alignment Healthcare Inc | Dawn Maroney | President | Sale of securities on an exchange or to another person at price $ 21.33 per share. | 02 Jan 2026 | 228,152 | 1,057,015 | - | 21.3 | 4,867,600 | Common Stock |
| Phathom Pharma Inc | L. Basta Steven | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 226,156 | 221,156 | - | - | Stock Option (Right to Buy) | |
| Upstream Bio Inc | Everett Rand Sutherland | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 224,080 | 2,732,700 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| JBG SMITH Properties | W. Matthew Kelly | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 218,750 | 2,377,023 | - | - | LTIP Units | |
| ORIC Pharma Inc | Pratik S. Multani | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 214,000 | 214,000 | - | - | Stock Option (right to buy) | |
| Flowers Foods Inc | Ryals McMullian | Director, Chairman and CEO | Sale of securities on an exchange or to another person at price $ 10.87 per share. | 02 Jan 2026 | 209,000 | 1,022,380 (0%) | 0% | 10.9 | 2,271,663 | Common Stock |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 208,333 | 208,333 | - | - | Restricted Stock Unit | |
| Ocugen Inc | Ramesh Ramachandran | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 207,300 | 209,100 (0%) | 0% | 0 | Common Stock | |
| Evolv Tech Holdings Inc (Class A) | John Kedzierski | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 207,000 | 215,000 | - | 0 | Class A Common Stock | |
| Evolv Tech Holdings Inc (Class A) | John Kedzierski | Director, President & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 207,000 | 414,000 | - | - | Restricted Stock Units | |
| ORIC Pharma Inc | Dominic G. Piscitelli | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 206,500 | 206,500 | - | - | Stock Option (right to buy) | |
| JBG SMITH Properties | W. Matthew Kelly | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 205,731 | 2,158,273 | - | - | LTIP Units | |
| Navan Inc Ordinary Shares | Benjamin A. Horowitz | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 15.77 per share. | 02 Jan 2026 | 202,729 | 7,992,267 | - | 15.8 | 3,197,036 | Class A Common Stock |
| Ocular Therapeutix Inc | Sanjay Nayak | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 197,650 | 197,650 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Todd Anderman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 197,650 | 197,650 | - | - | Stock Option (Right to Buy) | |
| Ocular Therapeutix Inc | Steve Lawrence Meyers | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 197,650 | 197,650 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Francis Burrows | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 185,000 | 185,000 | - | - | Option to purchase common stock | |
| MFA Fin Inc | Craig L. Knutson | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 176,916 | 1,426,514 | - | - | Phantom Shares | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 176,300 | 176,300 | - | - | Stock Option (Right to Buy) | |
| JBG SMITH Properties | W. Matthew Kelly | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 175,000 | 2,552,023 | - | - | LTIP Units | |
| Flowers Foods Inc | Ryals McMullian | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 172,170 | 1,333,988 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharma Inc | Ramiro Ribeiro | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 171,400 | 171,400 | - | - | Stock Option (Right to Buy) | |
| Sionna Therapeutics Inc | Elena H. Ridloff | CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 165,440 | 165,440 | - | - | Non-Qualified Stock Option (right to buy) | |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 165,000 | 165,000 | - | - | Restricted Stock Units | |
| Bicycle Therapeutics PLC (ADR) | Kevin Lee | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 165,000 | 640,310 | - | 0 | Ordinary Shares | |
| Utz Brands Inc (Class A) | Howard A. Friedman | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 159,007 | 394,135 | - | 0 | Class A Common Stock | |
| SharkNinja Inc | Mark Barrocas | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 158,800 | 158,800 | - | - | Restricted Share Units | |
| Monte Rosa Therapeutics Inc | Sharon Townson | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 158,000 | 158,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Jennifer Champoux | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 158,000 | 158,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 157,500 | 157,500 | - | - | Stock Option (Right to Buy) | |
| MFA Fin Inc | Bryan Wulfsohn | Pres. & Chief Invest. Ofcr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 155,979 | 845,772 | - | - | Phantom Shares | |
| Sionna Therapeutics Inc | Charlotte McKee | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 155,700 | 155,700 | - | - | Non-Qualified Stock Option (right to buy) | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Sale of securities on an exchange or to another person at price $ 3.82 per share. | 02 Jan 2026 | 150,957 | 710,685 (0%) | 0% | 3.8 | 576,656 | Common Shares |
| Compass Therapeutics Inc | Jonathan Anderman | General Counsel | Grant, award, or other acquisition of securities at price $ 5.17 per share. | 02 Jan 2026 | 150,000 | 171,000 | - | 5.2 | 775,500 | Common Stock |
| Design Therapeutics Inc | Julie Burgess | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 150,000 | 150,000 | - | - | Stock option (right to buy) | |
| Terns Pharma Inc | Amy Burroughs | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 150,000 | 210,315 | - | - | Common Stock | |
| Terns Pharma Inc | Amy Burroughs | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 150,000 | 0 | - | - | Restricted Stock Unit | |
| Netflix | Reed Hastings | Director | Sale of securities on an exchange or to another person at price $ 92.32 per share. | 02 Jan 2026 | 146,324 | 20,138 (0%) | 0% | 92.3 | 13,509,071 | Common Stock |
| Kenvue | Amit Banati | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 144,341 | 144,341 | - | - | Restricted Stock Units | |
| Cartesian Therapeutics Inc | Carsten Brunn | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 143,200 | 347,296 (0%) | 0% | 0 | Common Stock | |
| Sionna Therapeutics Inc | Caroline Stark Beer | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 139,340 | 139,340 | - | - | Non-Qualified Stock Option (right to buy) | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.83 per share. | 02 Jan 2026 | 139,245 | 115,274 | - | 34.8 | 4,849,555 | Common Stock |
| Monte Rosa Therapeutics Inc | Filip Janku | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 139,000 | 139,000 | - | - | Stock Option (Right to Buy) | |
| Oscar Health Inc (Class A) | Mario Schlosser | Director, President of Technology & CTO | Sale of securities on an exchange or to another person at price $ 15.02 per share. | 02 Jan 2026 | 137,933 | 360,215 | - | 15.0 | 2,071,754 | Class A Common Stock |
| Halliburton | Jefferey A. Miller | Director, Director, President & CEO | Grant, award, or other acquisition of securities at price $ 29.60 per share. | 02 Jan 2026 | 133,458 | 1,131,090 (0%) | 0% | 29.6 | 3,950,357 | Common Stock |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 32.29 per share. | 02 Jan 2026 | 132,454 | 2,600,246 (3%) | 0% | 32.3 | 4,277,032 | Common Stock, par value $0.00001 per share |
| Graphic Packaging Holding Co | Joseph P. Yost | EVP & President, Americas | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 132,014 | 132,014 | - | - | Service-Based Restricted Stock Units | |
| Janux Therapeutics Inc | Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 126,000 | 126,000 | - | - | Stock option (right to buy) | |
| Monte Rosa Therapeutics Inc | Philip Nickson | Chief Business & Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 126,000 | 126,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharma Inc | George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 126,000 | 126,000 | - | - | Stock Option (Right to Buy) | |
| Dyadic Intl Inc, DE | Mark A. Emalfarb | Director, CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 126,000 | 126,000 | - | - | Stock Option | |
| Compass Therapeutics Inc | Barry Shin | CFO | Grant, award, or other acquisition of securities at price $ 5.17 per share. | 02 Jan 2026 | 125,000 | 525,000 | - | 5.2 | 646,250 | Common Stock |
| JBG SMITH Properties | Madhumita Moina Banerjee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 125,000 | 414,094 | - | - | LTIP Units | |
| JBG SMITH Properties | George Laucks Xanders | Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 125,000 | 708,460 | - | - | LTIP Units | |
| Archer Aviation Inc (Class A) | Thomas Paul Muniz | CHIEF TECHNOLOGY OFFICER | Sale of securities on an exchange or to another person at price $ 8.00 per share. | 02 Jan 2026 | 125,000 | 1,272,129 | - | 8 | 1,000,000 | Class A Common Stock |
| Utz Brands Inc (Class A) | Howard A. Friedman | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 123,249 | 235,128 | - | 0 | Class A Common Stock | |
| Freshworks Inc (Class A) | Philippa Lawrence | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 120,870 | 511,248 | - | 0 | Class A Common Stock | |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 120,200 | 120,200 | - | - | Stock Option (right to buy) | |
| Figma Inc Ordinary Shares | Kris Rasmussen | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 36.97 per share. | 02 Jan 2026 | 119,406 | 10,760,587 | - | 37.0 | 4,414,559 | Class A Common Stock |
| Gossamer Bio Inc | Bryan Giraudo | COO/CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 115,750 | 389,737 (0%) | 0% | 0 | Common Stock | |
| ORIC Pharma Inc | Jacob M. Chacko | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 112,500 | 112,500 | - | - | Restricted Stock Unit | |
| Insmed Inc | William H. Lewis | Director, Chair and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 110,400 | 110,400 | - | - | Stock Option (right to buy) | |
| Goosehead Insurance Inc (Class A) | Mark K. Miller | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 110,000 | 110,000 | - | - | Employee Stock Options (right to buy) | |
| Janux Therapeutics Inc | Thomas DiRaimondo | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 109,900 | 109,900 | - | - | Stock option (right to buy) | |
| Cartesian Therapeutics Inc | Blaine Davis | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 109,000 | 109,000 | - | - | Employee Stock Option (right to buy) | |
| Sionna Therapeutics Inc | Jennifer Fitzpatrick | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 103,140 | 103,140 | - | - | Non-Qualified Stock Option (right to buy) | |
| Dyadic Intl Inc, DE | Mark A. Emalfarb | Director, CEO, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 102,609 | 4,832,667 (17%) | 0% | 0 | Common Stock | |
| LXP Industrial Trust | T. Wilson Eglin | Director, Chairman, CEO and President | Grant, award, or other acquisition of securities at price $ 49.58 per share. | 02 Jan 2026 | 101,654 | 832,674 (0%) | 0% | 49.6 | 5,040,005 | Common Shares |
| APA | John J. Christmann | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 101,540 | 705,522 (0%) | 0% | 0 | Common Stock | |
| APA | John J. Christmann | Director, CEO | Sale or transfer of securities back to the company at price $ 25.36 per share. | 02 Jan 2026 | 101,540 | 603,982 (0%) | 0% | 25.4 | 2,575,054 | Common Stock |
| APA | John J. Christmann | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 101,540 | 178,863 | - | - | Restricted Stock / Units | |
| Janux Therapeutics Inc | McIver Zachariah | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 101,500 | 101,500 | - | - | Stock option (right to buy) | |
| Stitch Fix Inc (Class A) | Katrina Lake | Director | 02 Jan 2026 | 101,150 | 101,150 (0%) | 0% | 0 | Class A Common Stock | ||
| Stitch Fix Inc (Class A) | Katrina Lake | Director | Sale of securities on an exchange or to another person at price $ 5.08 per share. | 02 Jan 2026 | 101,150 | 0 (0%) | 0% | 5.1 | 513,822 | Class A Common Stock |
| Stitch Fix Inc (Class A) | Katrina Lake | Director | 02 Jan 2026 | 101,150 | 7,205,388 | - | - | Class B Common Stock | ||
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 100,748 | 0 | - | - | Performance Restricted Stock Units | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 100,748 | 4,133,360 (7%) | 0% | 0 | Common Stock | |
| MFA Fin Inc | Bryan Wulfsohn | Pres. & Chief Invest. Ofcr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,735 | 689,793 | - | - | Phantom Shares | |
| Janux Therapeutics Inc | Charles Winter M. | Chief Technical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,100 | 100,100 | - | - | Stock option (right to buy) | |
| Halliburton | Lawrence J. Pope | EVP and Chief Admin Officer | Sale of securities on an exchange or to another person at price $ 32.25 per share. | 02 Jan 2026 | 100,000 | 419,799 (0%) | 0% | 32.3 | 3,225,000 | Common Stock |
| JBG SMITH Properties | Madhumita Moina Banerjee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 514,094 | - | - | LTIP Units | |
| JBG SMITH Properties | George Laucks Xanders | Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 808,460 | - | - | LTIP Units | |
| SharkNinja Inc | Neil Shah | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Restricted Share Units | |
| Kura Oncology Inc | Kathleen Ford | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Teresa Brophy Bair | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Mollie Leoni | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Option to purchase common stock | |
| Goosehead Insurance Inc (Class A) | Mark E. Jones | Director, Executive Chairman, Ten Percent Owner, Member of 10% owner group | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Employee Stock Options (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Michael Skynner | CHIEF TECHNOLOGY OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Alistair Milnes | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Alethia Young | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Bicycle Therapeutics PLC (ADR) | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAIN OFF | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Alignment Healthcare Inc | Dawn Maroney | President | Sale of securities on an exchange or to another person at price $ 20.03 per share. | 02 Jan 2026 | 100,000 | 1,285,167 | - | 20.0 | 2,003,450 | Common Stock |
| Graphic Packaging Holding Co | Elizabeth Spence | EVP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 99,010 | 99,010 | - | - | Service-Based Restricted Stock Units | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 97,357 | 97,357 | - | - | restricted share units | |
| Biodesix Inc | Scott Hutton | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 97,000 | 97,000 | - | - | Stock Options (Right to Buy) | |
| Oscar Health Inc (Class A) | Mario Schlosser | Director, President of Technology & CTO | Sale of securities on an exchange or to another person at price $ 15.64 per share. | 02 Jan 2026 | 96,928 | 350,180 | - | 15.6 | 1,515,954 | Class A Common Stock |
| The Baldwin Insurance Grp Inc (Class A) | Paul Eugene Sparks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 96,787 | 96,787 (0%) | 0% | - | Class A Common Stock | |
| Janux Therapeutics Inc | David Campbell | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 96,600 | 381,582 | - | 0 | Common Stock | |
| Upstream Bio Inc | Aaron Deykin | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 96,000 | 96,000 | - | - | Stock Option (Right to Buy) | |
| Protagonist Therapeutics Inc | Dinesh V. Patel | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 95,400 | 614,943 (2%) | 0% | 0 | Common Stock | |
| Gossamer Bio Inc | Richard Aranda | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 93,750 | 463,106 (0%) | 0% | 0 | Common Stock | |
| Gossamer Bio Inc | Robert Paul Smith | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 93,750 | 260,898 (0%) | 0% | 0 | Common Stock | |
| Sempra Energy | Justin C. Bird | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 93,349 | 93,349 | - | - | Employee Stock Option (right to buy) | |
| UDR | Thomas W. Toomey | Director, Chairman, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 92,798 | 1,276,209 | - | - | Class 2 LTIP Units | |
| Dropbox Inc (Class A) | Andrew W. Houston | Director, Chief Executive Officer, Ten Percent Owner | 02 Jan 2026 | 92,668 | 92,668 (0%) | 0% | 0 | Class A Common Stock | ||
| Dropbox Inc (Class A) | Andrew W. Houston | Director, Chief Executive Officer, Ten Percent Owner | 02 Jan 2026 | 92,668 | 66,841,625 | - | - | Class B Common Stock | ||
| JBG SMITH Properties | W. Matthew Kelly | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 91,569 | 2,643,592 | - | - | LTIP Units | |
| Upstream Bio Inc | Michael Paul Gray | CFO and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 91,500 | 91,500 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Greg S. Zante | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 91,000 | 91,000 | - | - | Stock Option (Right to Buy) | |
| Viking Therapeutics Inc | Marianna Mancini | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 91,000 | 91,000 | - | - | Stock Option (Right to Buy) | |
| Compass Therapeutics Inc | Carl L. Gordon | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Compass Therapeutics Inc | Ellen V. Chiniara | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Compass Therapeutics Inc | Richard S. Lindahl | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Compass Therapeutics Inc | Mary Ann Gray | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Compass Therapeutics Inc | Philip J. Ferneau | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Compass Therapeutics Inc | James P. Boylan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Markus Warmuth | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 634,538 | - | - | Common Stock | |
| Jasper Therapeutics Inc | Jeetinder Singh Mahal | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Silence Therapeutics PLC (ADR) | Timothy Mcinerney | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Share Option (Right to Buy) | |
| Silence Therapeutics PLC (ADR) | James Lawrence Ede-Golightly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Share Option (Right to Buy) | |
| Silence Therapeutics PLC (ADR) | David Jakob Lemus | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Share Option (Right to Buy) | |
| Goosehead Insurance Inc (Class A) | Mark E. Jones | CFO & COO, Ten Percent Owner, Member of 10% owner group | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 90,000 | 90,000 | - | - | Employee Stock Options (right to buy) | |
| Arcellx Inc | Michelle Gilson | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 88,542 | 88,542 | - | - | Restricted Stock Unit | |
| Whitestone REIT | David K. Holeman | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 87,576 | 842,443 (2%) | 0% | 0 | Common Shares | |
| UDR | David D. Bragg | SVP - Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 87,365 | 114,504 | - | - | Class 2 LTIP Units | |
| Insmed Inc | S. Nicole Schaeffer | Chief People Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.91 per share. | 02 Jan 2026 | 87,290 | 129,044 (0%) | 0% | 13.9 | 1,214,204 | Common Stock |
| Insmed Inc | S. Nicole Schaeffer | Chief People Strategy Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 87,290 | 0 | - | - | Stock Option (right to buy) | |
| Gaming and Leisure Properties Inc | Peter M. Carlino | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 87,010 | 6,101,510 (2%) | 0% | 0 | Common Stock | |
| Oscar Health Inc (Class A) | Mario Schlosser | Director, President of Technology & CTO | 02 Jan 2026 | 86,893 | 447,108 | - | - | Class A Common Stock | ||
| Oscar Health Inc (Class A) | Mario Schlosser | Director, President of Technology & CTO | 02 Jan 2026 | 86,893 | 1,532,293 | - | - | Class B Common Stock | ||
| EyePoint Pharma Inc | Ramiro Ribeiro | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 85,700 | 85,700 | - | - | Restricted Stock Units | |
| Ionis Pharma Inc | Brett P. Monia | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 85,410 | 85,410 | - | - | Non-Qualified Stock Option (right to buy) | |
| Fastenal | Daniel L. Florness | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 85,365 | 85,365 | - | - | Employee Stock Option (Right to Buy) | |
| Gossamer Bio Inc | Christian Waage | EVP, Tech Ops and Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 84,500 | 814,061 (1%) | 0% | 0 | Common Stock | |
| Gossamer Bio Inc | Caryn Peterson | EVP, Regulatory Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 84,500 | 259,333 (0%) | 0% | 0 | Common Stock | |
| LENZ Therapeutics Inc | Daniel R. Chevallard | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 84,200 | 84,200 | - | - | Stock Option (right to buy) | |
| LENZ Therapeutics Inc | Shawn Olsson | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 84,200 | 84,200 | - | - | Stock Option (right to buy) | |
| LENZ Therapeutics Inc | Marc Odrich | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 84,200 | 84,200 | - | - | Stock Option (right to buy) | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 84,000 | 0 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | Joel Lewis | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 84,000 | 916,592 (1%) | 0% | 0 | Common Stock | |
| Intuitive Machines Inc (Class A) | Stephen Altemus | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 83,914 | 1,110,316 | - | - | Class A Common Stock | |
| Intuitive Machines Inc (Class A) | Stephen Altemus | Director, Chief Executive Officer, Ten Percent Owner | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Jan 2026 | 83,914 | 13,258,299 | - | - | Class C Common Stock | |
| Intuitive Machines Inc (Class A) | Stephen Altemus | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 18.04 per share. | 02 Jan 2026 | 83,914 | 1,026,402 | - | 18.0 | 1,513,733 | Class A Common Stock |
| Intuitive Machines Inc (Class A) | Stephen Altemus | Director, Chief Executive Officer, Ten Percent Owner | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 83,914 | 13,258,299 | - | - | Common Units | |
| Apogee Therapeutics Inc | Jane Pritchett Henderson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 83,690 | 83,690 | - | - | Stock Option (Right to Buy) | |
| Apogee Therapeutics Inc | Carl Dambkowski | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 83,690 | 83,690 | - | - | Stock Option (Right to Buy) | |
| Fastenal | Daniel L. Florness | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 83,365 | 83,365 | - | - | Employee Stock Option (Right to Buy) | |
| Circle Internet Grp Inc (Class A) | Jeremy Allaire | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 83,018 | 15,890,330 | - | - | Class B Common Stock | |
| Phathom Pharma Inc | Narula Sanjeev | Chief Financial & Bus. Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 82,715 | 226,715 (0%) | 0% | 0 | Common Stock | |
| Workday (Class A) | David A. Duffield | Ten Percent Owner | 02 Jan 2026 | 81,479 | 186,528 (0%) | 0% | 0 | Class A Common Stock | ||
| Workday (Class A) | David A. Duffield | Ten Percent Owner | 02 Jan 2026 | 81,479 | 38,686,718 | - | - | Class B Common Stock | ||
| Dropbox Inc (Class A) | Andrew W. Houston | Director, Chief Executive Officer, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 26.79 per share. | 02 Jan 2026 | 79,363 | 13,305 (0%) | 0% | 26.8 | 2,126,381 | Class A Common Stock |
| Ocular Therapeutix Inc | Jeffrey S. Heier | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 79,112 | 326,425 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Donald Notman | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 79,112 | 389,292 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Nadia Waheed | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 79,112 | 326,280 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Peter Kaiser | Chief Development Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 79,112 | 271,918 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Namrata Saroj | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 79,112 | 254,620 (0%) | 0% | 0 | Common Stock | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 78,400 | 2,508,620 (3%) | 0% | 0 | Common Stock, par value $0.00001 per share | |
| Cartesian Therapeutics Inc | Milos Miljkovic | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 77,000 | 77,000 | - | - | Employee Stock Option (right to buy) | |
| Kratos Defense & Security Soln Inc | Deanna H. Lund | Director, EVP & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 75,000 | 75,000 | - | - | Restricted Stock Units | |
| KORU Medical Systems Inc | Thomas Adams | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 75,000 | 75,000 | - | - | Restricted Stock Units | |
| CarPartscom Inc | David Meniane | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 75,000 | 1,967,919 (5%) | 0% | 0 | Common Stock | |
| CarPartscom Inc | David Meniane | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 75,000 | 1,923,729 (5%) | 0% | 0 | Common Stock | |
| Bicycle Therapeutics PLC (ADR) | Travis Thompson | CHIEF ACCOUNTING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Upstream Bio Inc | Everett Rand Sutherland | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 75,000 | 75,000 | - | 0 | Common Stock | |
| Upstream Bio Inc | Adam Houghton | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Evolv Tech Holdings Inc (Class A) | John Kedzierski | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 7.03 per share. | 02 Jan 2026 | 74,322 | 140,678 | - | 7.0 | 522,484 | Class A Common Stock |
| CareTrust REIT Inc | David M. Sedgwick | President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 73,821 | 73,821 | - | - | LTIP Units | |
| Veritone Inc | Ryan Steelberg | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.79 per share. | 02 Jan 2026 | 73,538 | 832,535 (3%) | 0% | 4.8 | 352,247 | Common Stock |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 72,886 | 641,050 (0%) | 0% | - | Common Shares | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 72,886 | 597,667 | - | - | Restricted Share Units | |
| Circle Internet Grp Inc (Class A) | Jeremy Allaire | Director, Chairman and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 72,208 | 216,623 | - | - | Restricted Stock Units | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 71,762 | 0 | - | - | Restricted Stock Units | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 71,762 | 4,060,851 (7%) | 0% | 0 | Common Stock | |
| UiPath Inc (Class A) | Ashim Gupta | COO & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.39 per share. | 02 Jan 2026 | 71,621 | 624,496 | - | 16.4 | 1,173,868 | Class A Common Stock |
| Terns Pharma Inc | Amy Burroughs | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 38.10 per share. | 02 Jan 2026 | 71,339 | 138,976 | - | 38.1 | 2,718,230 | Common Stock |
| Cartesian Therapeutics Inc | Emily English | Chief Operations Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 71,000 | 71,000 | - | - | Employee Stock Option (right to buy) | |
| Sempra Energy | Karen L. Sedgwick | Executive VP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 70,418 | 70,418 | - | - | Employee Stock Option (right to buy) | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.87 per share. | 02 Jan 2026 | 70,037 | 69,188 | - | 35.9 | 2,511,919 | Common Stock |
| NRG Energy | Robert J. Gaudette | Exec VP, NRG Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 69,588 | 134,380 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| NRG Energy | Robert J. Gaudette | Exec VP, NRG Business | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 69,588 | 0 | - | - | Relative Performance Stock Units | |
| American Homes 4 Rent (Class A) | Bryan A. Smith | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 68,923 | 268,032 (0%) | 0% | 0 | Class A Common Shares | |
| ASGN Inc | Theodore S. Hanson | Director, CEO | Grant, award, or other acquisition of securities at price $ 46.66 per share. | 02 Jan 2026 | 68,581 | 128,081 (0%) | 0% | 46.7 | 3,199,989 | Common Stock |
| WEC Energy | Scott J. Lauber | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 68,111 | 68,111 | - | - | Stock Option (right to buy) | |
| Arcellx Inc | Christopher Heery | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 67,708 | 67,708 | - | - | Restricted Stock Unit | |
| Dyadic Intl Inc, DE | Jack L. Kaye | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 67,500 | 67,500 | - | - | Stock Option | |
| Dyadic Intl Inc, DE | Patrick K. Lucy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 67,500 | 67,500 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.25 per share. | 02 Jan 2026 | 67,473 | 254,519 | - | 14.2 | 961,490 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 67,473 | 108,334 | - | - | Stock Option | |
| UiPath Inc (Class A) | Ashim Gupta | COO & CFO | Sale of securities on an exchange or to another person at price $ 16.10 per share. | 02 Jan 2026 | 67,468 | 557,028 | - | 16.1 | 1,086,498 | Class A Common Stock |
| Dyadic Intl Inc, DE | Joseph Hazelton | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 67,250 | 67,250 | - | - | Stock Option | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 66,372 | 597,344 | - | - | Restricted Share Units | |
| BlackBerry Ltd | John J. Giamatteo | Director, CEO & President, Cybersecurity | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 66,372 | 777,057 (0%) | 0% | - | Common Shares | |
| Royalty Pharma PLC (Class A) | Terrance Coyne | EVP & CFO | Sale of securities on an exchange or to another person at price $ 38.42 per share. | 02 Jan 2026 | 65,832 | 460,828 | - | 38.4 | 2,528,982 | Class A Ordinary Shares |
| Rayonier Inc | Mark D. McHugh | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 65,479 | 294,933 (0%) | 0% | 0 | Common Shares | |
| JBG SMITH Properties | Evan Regan-Levine | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 65,000 | 213,307 | - | - | LTIP Units | |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 65,000 | 130,000 | - | - | Restricted Stock Units | |
| EyePoint Pharma Inc | Jay S. Duker | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 65,000 | 74,965 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Sanjay Nayak | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 64,900 | 342,760 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Todd Anderman | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 64,900 | 152,468 (0%) | 0% | 0 | Common Stock | |
| Ocular Therapeutix Inc | Steve Lawrence Meyers | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 64,900 | 217,628 (0%) | 0% | 0 | Common Stock | |
| Koppers Holdings Inc | Leroy M. Ball | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 64,634 | 0 | - | - | Restricted Stock Units | |
| Koppers Holdings Inc | Leroy M. Ball | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 64,634 | 449,094 (2%) | 0% | - | Common Stock | |
| Utz Brands Inc (Class A) | Howard A. Friedman | Director, CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.38 per share. | 02 Jan 2026 | 64,482 | 329,653 | - | 10.4 | 669,323 | Class A Common Stock |
| Regions Financial | Russell K. Zusi | SEVP & CRO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 64,102 | 105,887 (0%) | 0% | 0 | Common Stock | |
| Regions Financial | Russell K. Zusi | SEVP & CRO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 64,102 | 214,569 | - | - | Restricted Stock Units | |
| NRG Energy | Woo-Sung Bruce Chung | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 64,010 | 0 | - | - | Relative Performance Stock Units | |
| NRG Energy | Woo-Sung Bruce Chung | EVP & CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 64,010 | 132,625 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| EyePoint Pharma Inc | George O. Elston | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 63,000 | 63,000 | - | - | Restricted Stock Units | |
| PTC Therapeutics Inc | Matthew B. Klein | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 63,000 | 405,132 (0%) | 0% | 0 | Common Stock | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 62,529 | 627,128 (1%) | 0% | 0 | common shares | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 62,529 | 0 | - | - | restricted share units | |
| Compass Therapeutics Inc | Neil Lerner | Chief Accounting Officer | Grant, award, or other acquisition of securities at price $ 5.17 per share. | 02 Jan 2026 | 62,500 | 382,500 | - | 5.2 | 323,125 | Common Stock |
| NRG Energy | Brian E. Curci | Exec VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 61,790 | 0 | - | - | Relative Performance Stock Units | |
| NRG Energy | Brian E. Curci | Exec VP & General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 61,790 | 178,045 (0%) | 0% | 0 | Common Stock, par value $.01 per share | |
| American Battery Tech Co | Ryan Mitchell Melsert | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 61,413 | 2,865,003 (1%) | 0% | 0 | Common Stock | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 61,193 | 653,462 (1%) | 0% | 0 | common shares | |
| Imax Corp | Richard Lewis Gelfond | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 61,193 | 61,193 | - | - | restricted share units | |
| JBG SMITH Properties | George Laucks Xanders | Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 61,046 | 869,506 | - | - | LTIP Units | |
| Fastenal | Jeffery Michael Watts | President and Chief Sales Off. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 60,975 | 60,975 | - | - | Employee Stock Option (Right to Buy) | |
| NRG Energy | Brian E. Curci | Exec VP & General Counsel | Sale of securities on an exchange or to another person at price $ 161.71 per share. | 02 Jan 2026 | 60,580 | 93,089 (0%) | 0% | 161.7 | 9,796,392 | Common Stock, par value $.01 per share |
| Sempra Energy | Caroline A. Winn | Executive Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 60,429 | 60,429 | - | - | Employee Stock Option (right to buy) | |
| JBG SMITH Properties | Evan Regan-Levine | Chief Strategy Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 60,000 | 273,307 | - | - | LTIP Units | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 60,000 | 67,614 (0%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Jack W. Callicutt | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 60,000 | 0 | - | - | Restricted Stock Unit | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 60,000 | 60,000 (0%) | 0% | 0 | Common Stock | |
| Galectin Therapeutics Inc | Khurram Jamil | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 60,000 | 0 | - | - | Restricted Stock Unit | |
| Tango Therapeutics Inc | Sung H. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| Oscar Health Inc (Class A) | Mario Schlosser | Director, President of Technology & CTO | 02 Jan 2026 | 59,800 | 498,148 | - | - | Class A Common Stock | ||
| Oscar Health Inc (Class A) | Mario Schlosser | Director, President of Technology & CTO | 02 Jan 2026 | 59,800 | 1,619,186 | - | - | Class B Common Stock | ||
| Rigetti Computing Inc | Alissa M. Fitzgerald | Director | Sale of securities on an exchange or to another person at price $ 22.41 per share. | 02 Jan 2026 | 59,316 | 34,675 | - | 22.4 | 1,329,378 | Common Stock |
| JBG SMITH Properties | George Laucks Xanders | Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 59,259 | 574,064 | - | - | AO LTIP | |
| MFA Fin Inc | Michael C. Roper | Sr VP & Chief Financial Ofcr | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 58,492 | 279,973 | - | - | Phantom Shares | |
| JBG SMITH Properties | Madhumita Moina Banerjee | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 58,333 | 591,325 | - | - | AO LTIP | |
| Pagerduty Inc | Jennifer G. Tejada | Director, Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.39 per share. | 02 Jan 2026 | 57,730 | 1,288,488 (1%) | 0% | 12.4 | 715,275 | Common Stock |
| Spok Holdings Inc | Vincent D. Kelly | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 56,861 | 238,119 | - | - | Restricted Stock Unit | |
| Spok Holdings Inc | Vincent D. Kelly | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 56,861 | 294,980 | - | - | Restricted Stock Unit | |
| Somnigroup Intl Inc | Scott L. Thompson | Director, CEO & PRESIDENT | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 56,345 | 56,345 | - | - | Restricted Stock Units | |
| Imunon Inc | Stacy R. Lindborg | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 56,187 | 56,187 | - | - | Stock Option (Right to Buy) | |
| Halliburton | Shannon Slocum | Director, Directir, EVP and COO | Grant, award, or other acquisition of securities at price $ 29.60 per share. | 02 Jan 2026 | 56,178 | 219,229 (0%) | 0% | 29.6 | 1,662,869 | Common Stock |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 55,991 | 167,973 | - | - | Restricted Stock Unit | |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 55,991 | 782,467 | - | 0 | Common Stock | |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 55,459 | 673,378 | - | 0 | Common Stock | |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 55,459 | 55,459 | - | - | Restricted Stock Unit | |
| Sun Country Airlines Holdings Inc | Jude I. Bricker | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 55,211 | 178,558 | - | 0 | Common Stock, par value $0.01 per share | |
| Gaming and Leisure Properties Inc | Peter M. Carlino | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 55,000 | 110,000 | - | - | LTIP Units | |
| Gulfport Energy Corp - Ordinary Shares (New) | John K. Reinhart | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 54,558 | 96,116 (0%) | 0% | 0 | Common Stock | |
| Aurinia Pharma Inc | Matthew Donley | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 54,166 | 734,631 (0%) | 0% | 0 | Common Stock | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.00 per share. | 02 Jan 2026 | 53,630 | 187,046 | - | 16 | 858,080 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 53,630 | 30,388 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.53 per share. | 02 Jan 2026 | 53,470 | 61,804 | - | 35.5 | 1,899,554 | Common Stock |
| UDR | Michael D. Lacy | SVP-COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 53,392 | 399,663 | - | - | Class 2 LTIP Units | |
| Viking Therapeutics Inc | Brian Lian | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 33.38 per share. | 02 Jan 2026 | 53,279 | 2,546,967 (3%) | 0% | 33.4 | 1,778,267 | Common Stock, par value $0.00001 per share |
| Figma Inc Ordinary Shares | Kris Rasmussen | Chief Technology Officer | Sale of securities on an exchange or to another person at price $ 37.69 per share. | 02 Jan 2026 | 53,277 | 10,707,310 | - | 37.7 | 2,008,138 | Class A Common Stock |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 53,098 | 0 | - | - | Restricted Stock Unit | |
| Arcellx Inc | Rami Elghandour | Director, SEE REMARKS | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 53,098 | 726,476 | - | 0 | Common Stock | |
| UDR | Jon A. Grove | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 52,707 | 229,559 | - | - | Class 1 Performance LTIP Units | |
| Pearson PLC (ADR) | Omar P Abbosh | Executive Director,Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 10.50 per share. | 02 Jan 2026 | 52,025 | 805,779 (0%) | 0% | 10.5 | 546,330 | Ords 0.25p |
| Whitestone REIT | Christine J. Mastandrea | President and COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 51,998 | 462,929 (1%) | 0% | 0 | Common Shares | |
| SentinelOne Inc (Class A) | Tomer Weingarten | Director, President, CEO | 02 Jan 2026 | 51,595 | 1,197,203 | - | 0 | Class A Common Stock | ||
| SentinelOne Inc (Class A) | Tomer Weingarten | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 15.12 per share. | 02 Jan 2026 | 51,595 | 1,145,608 | - | 15.1 | 780,122 | Class A Common Stock |
| SentinelOne Inc (Class A) | Tomer Weingarten | Director, President, CEO | 02 Jan 2026 | 51,595 | 3,884,681 | - | - | Class B Common Stock | ||
| Upstream Bio Inc | Allison Ambrose | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 51,000 | 51,000 | - | - | Stock Option (Right to Buy) | |
| MFA Fin Inc | Harold E. Schwartz | Senior Vice President | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,369 | 300,061 | - | - | Phantom Shares | |
| Extreme Networks Inc | Edward B. Meyercord | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.70 per share. | 02 Jan 2026 | 50,000 | 1,921,418 (1%) | 0% | 6.7 | 335,000 | Common Stock |
| Extreme Networks Inc | Edward B. Meyercord | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 16.54 per share. | 02 Jan 2026 | 50,000 | 1,871,418 (1%) | 0% | 16.5 | 827,000 | Common Stock |
| Extreme Networks Inc | Edward B. Meyercord | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 324,573 | - | - | Non-Qualified Stock Option (right to buy) | |
| Global Indemnity Grp LLC (Class A) | Joseph W. Brown | Director, Chief Executive | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 500,000 | - | - | Option to Purchase Class A Common Shares (right to buy) | |
| JBG SMITH Properties | Steven A. Museles | Chief Legal Off. & Corp Secy | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 343,156 | - | - | LTIP Units | |
| Rush Street Interactive Inc (Class A) | Mattias Stetz | Chief Operating Officer | 02 Jan 2026 | 50,000 | 50,000 | - | 0 | Class A Common Stock | ||
| Rush Street Interactive Inc (Class A) | Mattias Stetz | Chief Operating Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 950,000 | - | 0 | Class V Voting Stock | |
| Rush Street Interactive Inc (Class A) | Mattias Stetz | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 19.09 per share. | 02 Jan 2026 | 50,000 | 0 | - | 19.1 | 954,355 | Class A Common Stock |
| Rush Street Interactive Inc (Class A) | Mattias Stetz | Chief Operating Officer | 02 Jan 2026 | 50,000 | 950,000 | - | - | Class A Common Units of Rush Street Interactive, L.P. | ||
| Warby Parker Inc (Class A) | David Gilboa | Director, Co-Chief Executive Officer | 02 Jan 2026 | 50,000 | 87,247 | - | 0 | Class A Common Stock | ||
| Warby Parker Inc (Class A) | David Gilboa | Director, Co-Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 24.29 per share. | 02 Jan 2026 | 50,000 | 37,247 | - | 24.3 | 1,214,500 | Class A Common Stock |
| Warby Parker Inc (Class A) | David Gilboa | Director, Co-Chief Executive Officer | 02 Jan 2026 | 50,000 | 4,784,923 | - | - | Class B Common Stock | ||
| Dyadic Intl Inc, DE | Seth J. Herbst | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 50,000 | - | - | Stock Option | |
| CarPartscom Inc | Kals Subramanian | Chief Technology Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 302,227 (0%) | 0% | 0 | Common Stock | |
| CarPartscom Inc | Michael Huffaker | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 403,684 (1%) | 0% | 0 | Common Stock | |
| PTC Therapeutics Inc | Eric Pauwels | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| PTC Therapeutics Inc | Pierre Gravier | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Sunrun Inc | Lynn Jurich | Director | Sale of securities on an exchange or to another person at price $ 19.28 per share. | 02 Jan 2026 | 50,000 | 701,175 (0%) | 0% | 19.3 | 963,880 | Common Stock |
| Kura Oncology Inc | Kathleen Ford | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 155,373 (0%) | 0% | 0 | Common Stock | |
| Kura Oncology Inc | Teresa Brophy Bair | Chief Legal Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 238,139 (0%) | 0% | 0 | Common Stock | |
| Kura Oncology Inc | Brian T. Powl | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 189,689 (0%) | 0% | 0 | Common Stock | |
| Kura Oncology Inc | Mollie Leoni | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 275,454 (0%) | 0% | 0 | Common Stock | |
| Bicycle Therapeutics PLC (ADR) | Michael Skynner | CHIEF TECHNOLOGY OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 168,277 | - | 0 | Ordinary Shares | |
| Bicycle Therapeutics PLC (ADR) | Alistair Milnes | CHIEF OPERATING OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 143,377 | - | 0 | Ordinary Shares | |
| Bicycle Therapeutics PLC (ADR) | Alethia Young | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 94,704 | - | 0 | Ordinary Shares | |
| Bicycle Therapeutics PLC (ADR) | Michael Charles Ferguson Hannay | CHIEF PROD & SUPPLY CHAIN OFF | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 103,102 | - | 0 | Ordinary Shares | |
| MiNK Therapeutics Inc | Jennifer S. Buell | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Pentair | John L. Stauch | Director, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 49,160 | 49,160 | - | - | Employee Stock Option (right to buy) | |
| Aurinia Pharma Inc | Joseph M. Miller | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 49,038 | 626,399 (0%) | 0% | 0 | Common Stock | |
| Portillos Inc Ordinary | Eugene I. Lee | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 49,019 | 60,798 | - | 0 | Class A common stock | |
| Aurinia Pharma Inc | Stephen P. Robertson | EVP, General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 48,558 | 557,434 (0%) | 0% | 0 | Common Stock | |
| Comcast (Class A) | Michael J. Cavanagh | Director, Co-CEO | 02 Jan 2026 | 48,439 | 359,867 | - | - | Phantom Stock | ||
| Sunopta Inc | Brian W. Kocher | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 48,134 | 145,926 (0%) | 0% | - | Common Shares | |
| Sunopta Inc | Brian W. Kocher | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 48,134 | 48,135 | - | - | Restricted Stock Units | |
| APA | Stephen J. Riney | President | Sale or transfer of securities back to the company at price $ 25.36 per share. | 02 Jan 2026 | 47,767 | 1 (0%) | 0% | 25.4 | 1,211,371 | Common Stock |
| APA | Stephen J. Riney | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 47,767 | 99,913 | - | - | Restricted Stock / Units | |
| APA | Stephen J. Riney | President | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 47,767 | 47,768 (0%) | 0% | 0 | Common Stock | |
| Dyadic Intl Inc, DE | Ping W. Rawson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 47,250 | 47,250 | - | - | Stock Option | |
| Dyadic Intl Inc, DE | Ronen Tchelet | VP of Research and Bus. Dvlpmt | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 47,250 | 47,250 | - | - | Stock Option | |
| JBG SMITH Properties | George Laucks Xanders | Chief Investment Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2026 | 47,024 | 583,460 | - | - | LTIP Units | |
| NRG Energy | Brian E. Curci | Exec VP & General Counsel | Sale of securities on an exchange or to another person at price $ 158.84 per share. | 02 Jan 2026 | 46,976 | 46,113 (0%) | 0% | 158.8 | 7,461,668 | Common Stock, par value $.01 per share |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.